Novo Nordisk was indirectly mentioned in the context of PepsiCo's financial performance. However, there was no direct mention of any impact on Novo Nordisk's business or stock price. Therefore, the news is unlikely to have a significant short-term impact on Novo Nordisk's stock price.

The CFO's statement suggests that the market for PepsiCo's products remains stable despite the prevalence of weight-loss drugs. This could indicate that consumer behavior towards the company's products has not significantly changed, which may maintain the stability of the company's stock price in the short term.